Therapeutic control of complement activation at the level of the central component C3.

ABSTRACT: The increasing recognition of the complement system's association with diseases of the inflammatory spectrum and with biomaterial and transplant-related complications has generated growing interest in the therapeutic modulation of this innate immune cascade. As a central functional hub that largely drives the activation, amplification, and effector generation of the complement response, the plasma protein C3 has long been recognized as an attractive target. While pharmacological modulation of C3 activation may offer a powerful opportunity to interfere with or even prevent complement-driven pathologies, the development of C3 inhibitors has often been accompanied by concerns regarding the safety and feasibility of this approach. Although no C3-targeted inhibitors have thus far been approved

SUBMITTER: Ricklin D 

PROVIDER: S-EPMC4675703 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature